Furthermore, as GLP-2 receptor agonists are used in the treatment of short bowel syndrome [34], and dual GLP-1/GLP-2 agonists are being investigated as potential weight loss therapies (NCT05788601) [35, 36], the glucometabolic effects of exogenous GLP-2 have gained renewed interest. The gene discussed is GCG; the disease is short bowel syndrome.